ArticleACS omega2026
Layered Zirconium Phosphate Nanocarriers for Mitoxantrone: Advancing Targeted Chemotherapy.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Layered zirconium phosphate nanoparticles (ZrPs), inorganic structures with a layered composition of zirconium atoms linked by phosphate groups, exhibit no cytotoxic effects on healthy or cancer cells, indicating a strong safety profile. We are investigating ZrP as a carrier for mitoxantrone (MTX), an anticancer drug that inhibits topoisomerase II and disrupts DNA synthesis but lacks selectivity between healthy and cancer cells. MTX shows prolonged retention in the body, with potential systemic toxicity affecting thyroid, hepatic, and cardiac tissues. We report a strategy to reduce systemic toxicity and protect healthy tissues from MTX by intercalating MTX into ZrP (MTX@ZrP), determining the conditions that affect MTX's release, and evaluating the cytotoxicity of MTX@ZrP on PC3 prostate cancer cells. MTX was intercalated within ZrP, forming MTX@ZrP nanoparticles, which were then characterized by Fourier transform infrared spectroscopy, scanning electron microscopy/energy-dispersive X-ray spectroscopy, z-potential analysis, and X-ray powder diffraction (XRPD) at different MTX:ZrP molar ratios. XRPD showed that MTX@ZrP has an expanded interlayer distance of 20.0 Å compared to the 7.6 Å interlayer distance of α-ZrP. Thermogravimetric analysis performed on all molar ratios of MTX to ZrP showed that the 1:1 MTX@ZrP molar ratio material had the highest drug loading of 13.8%. A drug release study to determine conditions affecting MTX liberation from ZrP at different pH levels using simulated body fluid and artificial lysosomal fluid showed that this process is pH-dependent. Cell viability studies with the androgen receptor-negative prostate cancer cell line PC3 showed that MTX@ZrP produces a cytotoxic effect. These findings help us envision a possible drug delivery approach that may greatly minimize adverse effects and harm to healthy tissues, offering promises for a more bearable cancer treatment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.